These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364 [Abstract] [Full Text] [Related]
3. Introducing human papillomavirus vaccines - questions remain. Paavonen J, Lehtinen M. Ann Med; 2008 May; 40(3):162-6. PubMed ID: 18382882 [Abstract] [Full Text] [Related]
4. Post-licensure monitoring of HPV vaccine in the United States. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Vaccine; 2010 Jul 05; 28(30):4731-7. PubMed ID: 20188681 [Abstract] [Full Text] [Related]
6. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Arbyn M, Dillner J. J Clin Virol; 2007 Mar 05; 38(3):189-97. PubMed ID: 17258503 [Abstract] [Full Text] [Related]
7. [Cervical cancer prevention: the impact of HPV vaccination]. Monsonégo J. Gynecol Obstet Fertil; 2006 Mar 05; 34(3):189-201. PubMed ID: 16529969 [Abstract] [Full Text] [Related]
8. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Lehtinen M, Idänpään-Heikkilä I, Lunnas T, Palmroth J, Barr E, Cacciatore R, Isaksson R, Kekki M, Koskela P, Kosunen E, Kuortti M, Lahti L, Liljamo T, Luostarinen T, Apter D, Pukkala E, Paavonen J. Int J STD AIDS; 2006 Apr 05; 17(4):237-46. PubMed ID: 16595046 [Abstract] [Full Text] [Related]
9. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Syrjänen KJ. Scand J Infect Dis Suppl; 2009 Apr 05; 107():3-32. PubMed ID: 19408160 [Abstract] [Full Text] [Related]
11. Evaluating the impact of human papillomavirus vaccines. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS. Vaccine; 2009 Jul 09; 27(32):4355-62. PubMed ID: 19515467 [Abstract] [Full Text] [Related]
12. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer. Ault K, Reisinger K. Int J Infect Dis; 2007 Nov 09; 11 Suppl 2():S26-8. PubMed ID: 18162242 [Abstract] [Full Text] [Related]
13. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Poljak M. Clin Microbiol Infect; 2012 Oct 09; 18 Suppl 5():64-9. PubMed ID: 22862799 [Abstract] [Full Text] [Related]
15. HPV vaccines: state of the art. D'Andrilli G, Bovicelli A, Giordano A. J Cell Physiol; 2010 Sep 09; 224(3):601-4. PubMed ID: 20432468 [Abstract] [Full Text] [Related]
16. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Adams M, Jasani B, Fiander A. Vaccine; 2007 Apr 20; 25(16):3007-13. PubMed ID: 17292517 [Abstract] [Full Text] [Related]
17. Prospects and prejudices of human papillomavirus vaccines in India. Das BC, Hussain S, Nasare V, Bharadwaj M. Vaccine; 2008 May 23; 26(22):2669-79. PubMed ID: 18455843 [Abstract] [Full Text] [Related]